Title:
Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 Patients
Date:

May 1, 2021

Author:
Reid Davison, Paul Kent, Jordan Tasse, et al.
Description:
Poster presentation for the 2021 American Society of Pediatric Hematology Oncology Conference

This poster presentation outlines Rush University Medical Center’s experience in treating FLC patients with a gemcitabine-oxaliplatin-lenvatanib (GEMOX-LEN) combination. This study describes the experiences of 16 patients, most of whom had multiple prior surgeries and systemic therapies, who were judged unresectable. The Rush University team chose gemcitabine-oxaliplatin (GEMOX) based on case reports of GEMOX efficacy in FLC, and combined it with the antiangiogenic/multi-kinase inhibitor lenvatanib. This combination was based on a treatment approach in the Children’s Oncology Group (COG) clinical trial AHEP1531 that uses a GEMOX-sorafenib combination, but substitutes lenvatanib for sorafenib based on an expectation of lower toxicity and more efficacy.

In this video, Dr. Paul Kent explains his poster presentation for the American Society of Pediatric Hematology Oncology

While the data is preliminary and uncontrolled, they found the combination to be a very promising option for FLC treatment in patients who are not surgical candidates, are widely metastatic or who have relapsed or progressed multiple times.

The poster is included below: